Credit Suisse Maintains on Cubist Pharmaceuticals

In a report published Friday, Credit Suisse analyst Jason Kantor maintained Outperform on

, with a $77.00 price target. According to the report, CBST previously released Q4 sales and provided a detailed pipeline update, so the call was more about 2014 guidance. “We believe revenue guidance was conservative and expect Cubicin to easily hit the high end of the range,” the report noted. “More importantly, investor focus in 2014 will be on new products – Tedizolid (PDUFA June 20) and CXA-201 (NDA filing in H1:14). We continue to expect CBST to perform well into these regulatory events, and note that FDA has become increasingly constructive in the field of antibiotics.” CBST closed Thursday at $75.38.